{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:10:16Z","timestamp":1790604616214,"version":"4.1.0"},"reference-count":50,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION<\/jats:title>\n                    <jats:p>We validated plasma phosphorylated tau (p\u2010tau)217 cut\u2010points for Alzheimer's disease (AD) diagnosis using two commercial assays in two biomarker\u2010defined cohorts and examined influences of pre\u2010analytical factors and chronic kidney disease (CKD) on p\u2010tau217 concentrations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      Lumipulse (Fujirebio) and ALZpath (Quanterix) assays quantified plasma p\u2010tau217 in symptomatic patients (AD status definition cerebrospinal fluid [CSF]\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0257; amyloid positron emission tomography [PET]\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a076). Receiver operating characteristic (ROC) analyses established \u2265\u00a095% sensitivity\/specificity cut\u2010points. In separate cohorts we evaluated the impact of pre\u2010analytical handling\/transport variations (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a040\/10) and cognitively normal (CN)\u2010CKD individuals (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a058).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Diagnostic accuracy was similar (area under the ROC Lumipulse 0.947; ALZpath 0.940). Lumipulse p\u2010tau217 achieved 95% sensitivity and 97% specificity using dual cut\u2010points (0.153\/0.422 pg\/mL), producing indeterminate results in 19.4% (CSF defined) and 34.2% (PET defined). P\u2010tau217 concentrations were stable across handling conditions and kit lots, and mostly in the low\u2010to\u2010intermediate range in CN\u2010CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION<\/jats:title>\n                    <jats:p>Lumipulse plasma p\u2010tau217, now available in our United Kingdom Accreditation Service\u2013accredited clinical National Health Service laboratory, will be used in a randomized trial of p\u2010tau217 result disclosure in memory services.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/alz.71147","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T12:00:53Z","timestamp":1771502453000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Alzheimer's Disease Diagnosis and Plasma Phospho\u2010Tau217 (ADAPT) study stage 1: Validating clinical cut\u2010points against CSF and amyloid PET"],"prefix":"10.1002","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1043-5721","authenticated-orcid":false,"given":"Ashvini","family":"Keshavan","sequence":"first","affiliation":[{"name":"Dementia Research Centre UCL Queen Square Institute of Neurology  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0576-7819","authenticated-orcid":false,"given":"Katharine","family":"Wiltshire","sequence":"additional","affiliation":[{"name":"Dementia Research Centre UCL Queen Square Institute of Neurology  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Wee","sequence":"additional","affiliation":[{"name":"King's College Hospital NHS Foundation Trust  London UK"},{"name":"Francis Crick Institute  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene Gorostiaga","family":"Belio","sequence":"additional","affiliation":[{"name":"Dementia Research Centre UCL Queen Square Institute of Neurology  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Tucker","sequence":"additional","affiliation":[{"name":"Dementia Research Centre UCL Queen Square Institute of Neurology  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Hart","sequence":"additional","affiliation":[{"name":"Neuroimmunology &amp; CSF Laboratory National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust (UCLH) Queen Square London  London UK"},{"name":"Department of Neuroinflammation UCL Queen Square Institute of Neurology  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Lunn","sequence":"additional","affiliation":[{"name":"Neuroimmunology &amp; CSF Laboratory National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust (UCLH) Queen Square London  London UK"},{"name":"MRC Centre for Neuromuscular Diseases UCL Queen Square Institute of Neurology  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C. B.","family":"David","sequence":"additional","affiliation":[{"name":"UK Dementia Research Institute Centre for Care Research and Technology  London UK"},{"name":"Department of Brain Sciences Imperial College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rizzo","sequence":"additional","affiliation":[{"name":"UK Dementia Research Institute Centre for Care Research and Technology  London UK"},{"name":"Department of Brain Sciences Imperial College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Sadeghi\u2010Alavijeh","sequence":"additional","affiliation":[{"name":"UCL Department of Renal Medicine University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Wilson","sequence":"additional","affiliation":[{"name":"UCL Department of Renal Medicine University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Gale","sequence":"additional","affiliation":[{"name":"UCL Department of Renal Medicine University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda J.","family":"Heslegrave","sequence":"additional","affiliation":[{"name":"UK Dementia Research Institute at UCL University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[{"name":"UK Dementia Research Institute at UCL University College London  London UK"},{"name":"Department of Psychiatry and Neurochemistry Institute of Neuroscience and Physiology the Sahlgrenska Academy at the University of Gothenburg  M\u00f6lndal Sweden"},{"name":"Clinical Neurochemistry Laboratory Sahlgrenska University Hospital  M\u00f6lndal Sweden"},{"name":"Hong Kong Center for Neurodegenerative Diseases  Hong Kong Special Administrative Region China"},{"name":"Wisconsin Alzheimer's Disease Research Center University of Wisconsin School of Medicine and Public Health University of Wisconsin\u2013Madison  Madison Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick C.","family":"Fox","sequence":"additional","affiliation":[{"name":"Dementia Research Centre UCL Queen Square Institute of Neurology  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paresh","family":"Malhotra","sequence":"additional","affiliation":[{"name":"UK Dementia Research Institute Centre for Care Research and Technology  London UK"},{"name":"Department of Brain Sciences Imperial College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Schott","sequence":"additional","affiliation":[{"name":"Dementia Research Centre UCL Queen Square Institute of Neurology  London UK"},{"name":"UK Dementia Research Institute at UCL University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12756"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02869-z"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00168-5"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00227-3"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01513-9"},{"key":"e_1_2_10_7_1","article-title":"The Alzheimer's Association Global Biomarker Standardization Consortium (GBSC) plasma phospho\u2010tau Round Robin study","volume":"21","author":"Ashton NJ","year":"2024","journal-title":"medRxiv"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12081836"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.12134"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12148-5"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13026"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa286"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12906"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12301"},{"key":"e_1_2_10_15_1","first-page":"1797","article-title":"Plasma p\u2010tau231 and p\u2010tau217 as state markers of amyloid\u2010\u03b2 pathology in preclinical Alzheimer's disease","volume":"28","author":"Mil\u00e0\u2010Alom\u00e0 M","year":"2022","journal-title":"Nat Med"},{"key":"e_1_2_10_16_1","article-title":"Plasma p\u2010tau217 predicts cognitive impairments up to ten years before onset in normal older adults","author":"Yakoub Y","year":"2024","journal-title":"medRxiv"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14140"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awae368"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14315"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awae346"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-023-00471-5"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01822-2"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12510"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_2_10_25_1","unstructured":"Donepezil galantamine rivastigmine and memantine for the treatment of Alzheimer's disease (TA217). National Institute for Health and Care Excellence; 2024."},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03622-w"},{"key":"e_1_2_10_27_1","unstructured":"FDA.Evaluation of automatic class III designation for Lumipulse G \u03b2\u2010Amyloid Ratio (1\u201042\/1\u201040) Decision Summary. In: Immunology editor.2022."},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102953"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2021-003310"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1159\/000351671"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51749"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcab035"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.5216"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.15757"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12168"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12510"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-024-00977-5"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01630-5"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14508"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05311-5"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.082874"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01391-1"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.078393"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70752"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/13872877241299047"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70765"},{"key":"e_1_2_10_47_1","article-title":"Effects of obesity on plasma biomarker and amyloid PET trajectories in Alzheimer's disease","volume":"17","author":"Mohammadi S","year":"2025","journal-title":"Alzheimers Dement"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanhl.2024.07.013"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210287"},{"key":"e_1_2_10_50_1","unstructured":"Algeciras\u2010SchimnichA Ashrafzadeh\u2010KianS BornhorstJ et\u00a0al.Performance of the Lumipulse plasma p\u2010tau217 assay to assess eligibility for amyloid\u2010lowering therapies.Alzheimer's Association International Conference. Toronto.2025."},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70173"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.71147","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/alz.71147","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.71147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:54:05Z","timestamp":1782539645000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.71147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/alz.71147"],"URL":"https:\/\/doi.org\/10.1002\/alz.71147","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"2025-09-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71147"}}